<DOC>
	<DOCNO>NCT00637195</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish necessary cause cervical cancer . The current Phase 3b study design assess immunogenicity safety commercially available vaccine co-administered GlaxoSmithKline Biologicals ' HPV vaccine GSK580299 healthy female subject .</brief_summary>
	<brief_title>Immunogenicity Safety Commercially Available Vaccine Co-administered With GSK HPV Vaccine ( 580299 )</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A female , include , 20 25 year age time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history history direct clinical examination enter study . Subjects must pregnant . Subjects must nonchildbearing potential , childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day dose vaccine . Administration routine vaccine meningococcal , inactivated influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day first dose study vaccine allow . Concurrently participate another clinical study , time study period ( Month 13 ) , subject expose investigational noninvestigational product ( pharmaceutical product device ) . A subject planning become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period two month last vaccine dose . Pregnant breastfeed woman . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period Previous administration component investigational vaccine . Previous vaccination hepatitis B plan administration hepatitis B vaccine foreseen study protocol study period . History hepatitis B infection . Known exposure hepatitis B within previous 6 week . Known acute chronic , clinically significant neurologic , hepatic renal functional abnormality , determine previous physical examination laboratory test . Cancer autoimmune disease treatment . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Human papillomavirus ( HPV ) vaccine</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Cervical cancer</keyword>
	<keyword>HPV</keyword>
	<keyword>Papillomavirus</keyword>
</DOC>